Isoniazid and rifapentine treatment effectively reduces persistent M. tuberculosis infection in maca...
Isoniazid and rifapentine treatment effectively reduces persistent M. tuberculosis infection in macaque lungs
About this item
Full title
Author / Creator
Sharan, Riti , Ganatra, Shashank R. , Singh, Dhiraj K. , Cole, Journey , Foreman, Taylor W. , Thippeshappa, Rajesh , Peloquin, Charles A. , Shivanna, Vinay , Gonzalez, Olga , Day, Cheryl L. , Gandhi, Neel R. , Dick, Edward J. , Hall-Ursone, Shannan , Mehra, Smriti , Schlesinger, Larry S. , Rengarajan, Jyothi and Kaushal, Deepak
Publisher
United States: American Society for Clinical Investigation
Journal title
Language
English
Formats
Publication information
Publisher
United States: American Society for Clinical Investigation
Subjects
More information
Scope and Contents
Contents
A once-weekly oral dose of isoniazid and rifapentine for 3 months (3HP) is recommended by the CDC for treatment of latent tuberculosis infection (LTBI). The aim of this study is to assess 3HP-mediated clearance of M. tuberculosis bacteria in macaques with asymptomatic LTBI. Twelve Indian-origin rhesus macaques were infected with a low dose (~10 CFU...
Alternative Titles
Full title
Isoniazid and rifapentine treatment effectively reduces persistent M. tuberculosis infection in macaque lungs
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9479578
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9479578
Other Identifiers
ISSN
1558-8238,0021-9738
E-ISSN
1558-8238
DOI
10.1172/JCI161564
